Neuroscience Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-BUO-220047. DOP: April 2022.

      The Patient Experience: Neurogenic detrusor overactivity (NDO) can impact on patients' quality of life in many ways

      Definition of NDO: NDO is characterised by overactivity of the bladder due to a relevant neurological condition5,6

      NDO can impact on patients' quality of life in many ways7

      Adapted from Tubaro, 2004.7

      Consequences of untreated NDO7-9

      Adapted from Tubaro, 2004.7

      Spinal lesions caused by a trauma, such as spinal cord injury, or by a progressive neurological condition, such as multiple sclerosis can lead to NDO10,11

      Expanded Disability Status Scale12,13

      Adapted from Fowler et al, 200912

      • Approximately 80% of patients with MS report some form of UI14
        • Frequency, urgency and UI are all commonly reported
      • 62% of patients with MS have NDO without bladder outlet obstruction15
      • Voiding LUTS are prevalent; in approximately 5–10% of patients, bladder symptoms are present at the onset of MS16

      DDAVP: desmopressin; CIC: clean intermittent catheterisation; BoNT/A: botulinum toxin type A; IDC: indwelling catheter; LUTS: lower urinary tract symptoms; MS: multiple sclerosis; NDO: neurogenic detrusor overactivity; QoL: quality of life; UI: urinary incontinence.

      BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord  injury (traumatic or non-traumatic), or multiple sclerosis.5

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
      4. Allergan. Data on file. 014
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed April 2022
      6. Salvatore S et al. Pathophysiology of Urinary Incontinence, Faecal Incontinence and Pelvic Organ Prolapse. Abrams P et al. Incontinence: 6th edition. 2017:50
      7. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004;64(suppl 6A);2–6
      8. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis 2007;13:915–928
      9. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep 2014;15:448
      10. Abrams P et al. Incontinence: 6th Edition 2017;50
      11. European Association of Urology Guidelines on Neuro-Urology. 2019. Available at: https://uroweb.org/. Accessed April 2022
      12. Fowler C J, Panicker JN et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Mrd J 2009;85:552-559
      13. Multiple Sclerosis Trust. Expanded Disability Status Scale (EDSS). Available at: https://www.mstrust.org.uk/. Accessed April 2022
      14. National US MS Society. Symptoms: bladder dysfunction. Autoimmune disease. Available at: https://www.nationalmssociety.org/. Accessed April 2022
      15. Kalsi V and Fowler C J. Therapy insight: bladder dysfunction associated with multiple sclerosis. Nature Clinical Practice Urology 2005;2:492–501
      16. McCombe P A, Gordan T P and Jackson M W. Bladder dysfunction in multiple sclerosis. Expert Rev Neurotherap 2009;9:331–340

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.

      BOTOX® PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: April 2022. UK-BUO-220026.